Impact of Mean Platelet Volume on Combined Safety Endpoint and Vascular and Bleeding Complications following Percutaneous Transfemoral Transcatheter Aortic Valve Implantation

Table 1

Baseline and procedural characteristics of study population.

Patient characteristics (𝑛=330)	Values
Age, years^†	81 (76–85)
Male : female (n)	165 : 165
Body mass index, (kg/m^2*)	26.43±4.81
Body surface area, (m^2*)	1.78±0.18
Previous myocardial infarction (n (%))	62 (18.8%)
Previous percutaneous coronary intervention (n (%))	62 (18.8%)
Previous coronary artery Bypass Grafting (n (%))	63 (19.1%)
Coronary artery disease (n (%))	125 (38.8%)
Diabetes mellitus (n (%))	95 (28.9%)
Current smoker (n (%))	10 (3.0%)
Hypertension (n (%))	244 (74.2%)
Hyperlipidaemia (n (%))	194 (59.0%)
Left ventricular ejection fraction <35% (n (%))	48 (14.7%)
Cerebrovascular disease (n (%))	41 (12.5%)
Chronic kidney disease (n (%))	100 (30.5%)
Pulmonary hypertension (n (%))	56 (17.4%)
Chronic obstructive airways disease (n (%))	101 (30.7%)
Peripheral arterial disease (n (%))	75 (22.9%)
Logistic Euroscore^†	18.54 (11.16–30.57)
STS-PROM^†	5.5 (3.6–9.1)
Antiplatelet use (none : single : dual) (n)	37 : 86 : 206
Proton-pump inhibitor use (n (%))	254 (81.2%)
Aortic annulus diameter, (mm^†)	24 (22–25)
Sheath size, (mm^†)	18 (18-19)
White cell count, (×10^9/L^†)	6.55 (5.33–8.0)
Red cell count, (×10^12/L*)	4.23±0.59
Haemoglobin, (g/dL*)	12.17±1.72
Mean corpuscular volume, (fL^†)	89.55 (89.83–93.30)
Red blood cell distribution width, (%^†)	14.7 (13.8–16.0)
Platelet count, (×10^9/L*)	201.43±72.37
Mean platelet volume, (fL*)	10.94±1.13

Values are expressed as mean ± SD* or median (IQR)^† or number (% of patients).
STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality.